Varicella Vaccine
Asset
Induces protective immunity against varicella-zoster virus.
- Stage
- Phase 2
- Modality
- Vaccine
- Target
- Not known
- 0
- Indications
- 28
- Trials
- 1
- Developer
Indications
1No named disease
Phase 2, Completed, NCT03375502, clinicaltrials.gov, Oct 20, 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials28
- Evidence for its targets1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.